Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952440 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31341995 | 0.87 | PIK3CA (0.43) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20839867 | 0.87 | HDAC1 (0.43) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9951657 | 0.85 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL20554184 | 0.85 | SMN1; SMN2 (0.51) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11589979 | 0.85 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1983363 | 0.76 | PIK3CA (0.64) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9955853 | 0.74 | ALDH1A1 (0.45) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29644660 | 0.74 | ALDH1A1 (0.45) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1121389 | 0.73 | NPC1 (0.50) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| CN-109963849-B | Nitrogen-containing heterocyclic compounds as FXR modulators | 和博医药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-03-18 | — | — | US | disclosed |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-03-18 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
| EP-3535260-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | Hepagene Therapeutics, Inc. (VG) | 2019-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | NR1H4, FXR1, FXR2 | KDM4E 4343/4885ALDH1A1 4338/4885SMN1; SMN2 4820/4885 |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | NR1H4, FXR1, FXR2 | KDM4E 4343/4885ALDH1A1 4338/4885SMN1; SMN2 4820/4885 |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | NR1H4, FXR1, FXR2 | KDM4E 4343/4885ALDH1A1 4338/4885SMN1; SMN2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.